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Aims: To determine the outcome of colorectal liver metastasis (CRLM) patients based on tumour burden,
represented by tumour number and size, and tumour biology as assessed by an inflammatory response
to tumour (IRT) and margin positivity.
Methods: Data were collated from CRLM patients undergoing resection from January 1993 to March
2007. Patients were divided into: low (3 metastases and/or 3 cm); moderate (4–7 metastases and/or
>3–5 cm); and high (8 metastases and/or >5 cm) tumour burden.
Results: Seven hundred and five patients underwent resection, of which 154 (21.8%), 262 (37.2%) and
289 (41.0%) patients were in the low, moderate and high tumour burden groups, respectively. The 5-year
disease-free (P < 0.001) and overall (P < 0.001) survival were significantly different between the groups.
IRT (P < 0.001), extent of resection (P < 0.001) and margin (P < 0.001) also differed between the
groups.Sub-group analysis revealed that IRT was the only adverse predictor for disease-free and overall
survival in the low group. In the moderate group, IRT predicted poorer disease-free survival on multi-
variate analysis. In the high group, R1 resection and transfusion were predictors of poorer disease-free
survival and age 65 years, R1 resection and IRT were adverse predictors of overall survival.
Conclusion: Resection margin influenced the outcome of patients with high tumour burden, hence the
importance of achieving clear margins. IRT influenced the outcome of patients with less aggressive
disease.
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Introduction
Hepatic resection is the only treatment modality associated with
long-term survival in patients with colorectal liver metastases
(CRLM). Despite variability in criteria for patient selection, 5-year
survival rates have ranged consistently from 25% to 58% with
most recent series now reporting in excess of 50%.1–5 In contrast,
the median survival of patients with untreated disease ranges
from 6–12 months,6,7 and the addition of optimal chemotherapy
regimens only improves their median survival to approximately
20 months.8–10
In 1986, Ekberg et al. concluded that resection for CRLM was
only indicated in patients with less than four liver metastases
including bilobar cases, no evidence of extra-hepatic disease and
when a resection margin of at least 10 mm could be achieved.11
With a better understanding of hepatic segmental anatomy,
refined haemostatic techniques,12,13 ‘down-sizing’ chemotherapy
and portal vein embolization,14 more patients are being subjected
to hepatic resection, including patients considered unresectable
previously. The benefits of surveillance after resection of CRLM
have been exemplified by studies that have reported up to
40% survival at 5-years following repeat hepatic resection for
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recurrence of CRLM, with acceptable morbidity and mortality
rates.15–18 Recent data have suggested that if lung metastases of
colorectal origin are resectable, 5-year survival after thoracotomy
is similar to that observed in patients following resection of
CRLM.19,20 These results reflect a more aggressive approach being
adopted towards the treatment of metastatic colorectal disease.
Although the selection criteria for resection of CRLM have
expanded over the past two decades, there is still no consensus as
to specific selection criteria for surgical resection in these patients.
Several clinico-pathological features such as: size of the largest
hepatic metastasis; number of hepatic metastases; distribution of
hepatic tumours; extent of hepatic resection; and status of resec-
tion margin have been identified as prognostic factors.21–24 Recent
published literature from this unit has shown a correlation
between the presence of pre-operative systemic inflammation,
represented by the expression of C-reactive protein (CRP)25 and
an elevation in neutrophil to lymphocyte ratio (NLR),26 with
poorer cancer-specific survival in patients with CRLM. This sug-
gests the presence of a host’s systemic inflammatory response to a
tumour (IRT), and may play a significant role in determining the
‘aggressiveness’ of tumour biology and prognosis. Nevertheless,
the interplay of tumour biology and surgical technique remains to
be elucidated.
The aim of the present study was to analyse the impact of
well-established prognostic factors on outcome in patients under-
going hepatic resection for CRLM based on the extent of tumour
burden defined by tumour number and size. Further analysis was
conducted in these groups to determine the impact of surgical
technique, represented by resection margin, and tumour biology
as reflected by IRT, on outcome.
Patients and methods
Patients
Patients with CRLM undergoing hepatic resection at the Hepato-
biliary Unit, St James’s University Hospital (SJUH), Leeds, United
Kingdom, during the 14-year period from January 1993 to March
2007, were identified from the hepatobiliary database. Patients
who had primary hepatic resection during the study period were
included in the analysis, whereas those undergoing repeat resec-
tions were excluded.
Demographic data included patient age, gender, disease presen-
tation and laboratory analyses (white cell counts with differentials
and CRP). The white cell and differential counts as well as CRP
were taken on the day prior to surgery with none of the patients
showing clinical symptoms or signs of sepsis. The neutrophil to
lymphocyte ratio (NLR) was calculated from the differential
count by dividing the absolute neutrophil count by the absolute
lymphocyte count. A NLR 5 was considered raised in accor-
dance with published literature.27 The unit does not routinely
measure CRP pre-operatively, and in patients with a pre-operative
CRP measured, a CRP level >10 mg/l was considered elevated.25
Systemic IRT was defined as an elevation in pre-operative NLR
and/or CRP above the normal reference ranges. Pre-operative
radiological assessment included a computed tomography (CT)
scan of the thorax, abdomen and pelvis and magnetic resonance
imaging (MRI) of the liver.
A subgroup of patients received neo-adjuvant Oxaliplatin-
based chemotherapy in order to ‘down-size’ disease before resec-
tion. These patients received six cycles of chemotherapy followed
by re-assessment prior to resection. According to the unit’s pro-
tocol, all patients received adjuvant chemotherapy comprising of a
24-week treatment with 5-fluorouracil and folinic acid, unless
they had underwent chemotherapy adjuvant to bowel resection
within 12 months of the primary hepatic resection.
Surgery
Parenchymal transection was performed using the Cavi-Pulse
Ultrasonic Surgical Aspirator (CUSA, Model 200T; Valley Labo-
ratory, Boulder, CO, USA). Intra-operative ultrasound was per-
formed to confirm the findings of pre-operative imaging and to
assist in surgical planning. The number of hepatic (Couinaud’s)
segments resected was determined by the procedure performed as
stated in the Brisbane nomenclature.28 In cases where multiple
resections were performed at a single setting, the most extensive
resection was considered the main procedure, with others listed as
additional hepatic procedures. In the present study, the extent of
hepatic resection was classified into two groups: less than hemi-
hepatectomy and hemi-hepatectomy or more. Transfusion of
blood products (packed red cells or whole blood) during surgery
or during subsequent in-hospital stay after surgery was also
recorded. Blood transfusion was indicated in patients with a hae-
moglobin less than 8 g/dl and symptomatic patients with a hae-
moglobin of 8–10 g/dl.
Histology
Histopathological data regarding the resected specimen were col-
lated. This included: tumour size in maximum diameter; tumour
number; and status of resection margin. R0 resection was defined
as no microscopic evidence of tumour at or within 1 mm of the
margin. The extent of tumour burden in patients with CRLM was
based on tumour number and size in surgical specimens, and
patients were divided into three groups: low (3 metastases
and/or 3 cm); moderate (4–7 metastases and/or >3–5 cm); and
high (8 metastases and/or >5 cm) tumour burden.
Follow-up
Patients were followed up at specialist hepatobiliary clinics. After
an initial post-operative review at 1 month, all patients were exam-
ined in the outpatient clinic at 3, 6, 12, 18 and 24 months and
annually thereafter. At each clinic review, blood tests were per-
formed for liver function tests and CEA levels. Patients underwent
3-monthly CT scans of the thorax, abdomen and pelvis during the
first 2 post-operative years, followed by 6 monthly thereafter for 3
years (year 3–5). A CT scan was next performed annually at 7 to 10
years of follow-up. Liver MRI was used to define suspicious lesions
demonstrated on CT or in cases of negative CT with rising tumour
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markers. Development of symptoms prompted an earlier review
than scheduled. Recurrence was defined as the development of new
liver metastases or metastases elsewhere on CT or MRI after resec-
tion. Overall and disease-free survival data were recorded.
Statistical analysis
Categorical data were presented as frequency and proportions (%)
and were analysed using the Pearson’s c2 test. The Kaplan–Meier
method was used to assess the survival and disease recurrence rate.
Univariate analysis was performed to assess for a significant dif-
ference in clinico-pathological characteristics that influenced
disease recurrence after curative resection. A multi-variate analysis
was performed using Cox regression (Step-wise forward model)
for variables significant on univariate analysis. All statistical analy-
ses were performed using the SPSS for WindowsS version 15.0
(SPSS Inc., Chicago, IL, USA), and statistical significance was
taken at the 5% level.
Results
Demographics
During the study period, 705 patients underwent primary hepatic
resections for CRLM at SJUH, of which 434 (61.6%) patients
developed recurrence and 363 (51.5%) patients died. The median
follow-up period of the patients currently alive was 24 months
(range: 6–168 months).
The median age at diagnosis was 63 years (range: 26–87 years).
Synchronous colon and liver disease was present in 298 (42.3%)
patients. Demographics and clinical factors are shown in
Table 1.
Anatomically based resections were performed in 524 (74.3%)
patients and 183 (26.0%) patients had a combination of an ana-
tomical with a non-anatomical resection (Table 2). There were 25
(3.5%) post-operative deaths.
There were 456 (64.7%) patients with two or more tumours
resected [median tumours resected per patient = 2 (range: 1–21)].
The majority of tumours were less than 50 mm in maximum
diameter (n = 400, 56.7%).
Clinico-pathological factors and outcome based on
tumour burden
Patients in the high tumour burden group were more likely to
have a systemic IRT, have a hemi-hepatectomy or more and have
tumour involvement at the resection margin (Table 1) than
patients in either of the other groups.
The disease-free survival in the low, moderate and high tumour
burden groups is shown in Fig. 1. There was also a significant
difference in the 1-, 3- and 5-year overall survival in these three
groups: 95.3%, 89.1% and 80.5%; 72.9%, 51.2% and 41.5%; and
50.8%, 32.4% and 27.0%, respectively (P < 0.001).
Table 1 Clinical, operative and pathological characteristics with respect to tumour burden
Prognostic factors Tumour burden P-value
Low
(n = 154)
Moderate
(n = 262)
High
(n = 289)
Age (years)
<65 74 (48.1%) 140 (53.4%) 148 (51.2%) 0.569
65 80 (51.9%) 122 (46.6%) 141 (48.8%)
Gender
Male 92 (59.7%) 167 (63.7%) 187 (64.7%) 0.575
Female 62 (40.3%) 95 (36.3%) 102 (35.3%)
Presentation
Synchronous 60 (39.0%) 99 (37.8%) 139 (48.1%) 0.164
Metachronous 94 (61.0%) 163 (62.2%) 150 (51.9%)
IRT*
Yes 16 (14.0%) 33 (16.3%) 67 (29.5%) <0.001
No 98 (86.0%) 169 (83.7%) 160 (70.5%)
Extent of resection
Less than hemi-hepatectomy 102 (66.2%) 100 (38.2%) 61 (21.1%) <0.001
Hemi-hepatectomy or more 52 (33.8%) 162 (61.8%) 228 (78.9%)
Blood transfusion 32 (20.8%) 61 (23.3%) 56 (19.4%) 0.529
Morbidity 59 (38.3%) 102 (38.9%) 130 (45.0%) 0.248
Resection margin
R1 (Involved) 35 (22.7%) 83 (31.7%) 140 (48.4%) <0.001
R0 (1 mm) 119 (77.3%) 179 (68.3%) 149 (51.6%)
*IRT was available in 543 (77.0%) patients, with 114 (74.0%), 202 (77.1%) and 227 (78.5%) patients, respectively, in the low, moderate and high
tumour burden groups.
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Predictors of disease-free and overall survival
Several clinical, operative and pathological factors affecting
disease-free survival were identified on both univariate and mul-
tivariate analysis and are shown in Table 3. Similarly predictors of
poorer overall survival are shown in Table 4.
Impact of systemic IRT and resection margin based
on tumour burden
For patients in the low tumour burden group, raised pre-operative
IRT was the only adverse predictor of disease-free [median
(range) survival of no IRT was 48 (2–108) months vs. median
(range) survival of IRT was 15 (3–72) months, P < 0.001] and
overall survival (Fig. 2).
With respect to the moderate tumour burden group, factors
associated with poorer disease-free and overall survival are shown
in Table 5 and Fig. 3, respectively.
Prognostic factors for disease-free and overall survival in
patients who fulfilled the criteria for high tumour burden are
shown in Table 6a and b, respectively. The effect of pre-operative
IRT and resection margin status on overall survival for those
patients with high tumour burden are shown in Fig. 4a and b,
respectively. Table 7 summarizes the independent clinico-
pathological variables that significantly influenced outcome based
on the extent of tumour burden.
Discussion
Hepatic resection for CRLM has consistently achieved good long-
term disease-free and overall survival based on absence of recur-
rence29,30 and is in stark contrast to the outcome of patients with
unresectable disease.31 Although the selection criteria for resection
have expanded over the past two decades, little exists by way of a
consensus for selecting patients who would benefit most from
surgery and adjuvant chemotherapy.
Patient selection for liver resection is currently based on resec-
tability of all macroscopic disease with clear margins while leaving
sufficient residual functioning liver volume, decisions dependent
on results of cross-sectional imaging with CT and/or MRI. These
criteria apply to solitary, multiple and bilobar disease as well as
patients with extra-hepatic disease that is confined to the lungs,
spleen or adrenal glands.32 The selection of patients with CRLM
for resection with curative intent based on these guidelines differ
significantly compared with the one proposed by Ekberg et al.11
Table 2 Operative details of patients in this study
Operative data
Major hepatic resection (Hemi-hepatectomy or more) 442 (62.7%)
Left hemihepatectomy (resection of segments
2,3,4 +/- 1)
20 (4.5%)
+ Non-anatomical resection 15 (3.4%)
Right hemihepatectomy (resection of segments
5,6,7,8 +/- 1)
143 (32.4%)
+ Non-anatomical resection 69 (15.6%)
Left trisectionectomy (resection of segments
2,3,4,5,8 +/- 1)
35 (7.9%)
+ Non-anatomical resection 14 (3.2%)
Right trisectionectomy (resection of segments
4,5,6,7,8 +/- 1)
102 (23.0%)
+ Non-anatomical resection 44 (10.0%)
Minor hepatic resection (Less than hemi-hepatectomy) 263 (37.3%)
Left lateral sectionectomy (resection of segments
2 and 3)
34 (12.9%)
+ Non-anatomical resection 29 (11.0%)
+ Right posterior sectionectomy 4 (1.5%)
+ Transverse hepatectomy 1 (0.4%)
Right posterior sectionectomy (resection of segment
6 and 7)
5 (1.9%)
+ Non-anatomical resection 6 (2.3%)
Transverse hepatectomy (resection of segment
4B, 5 and 6)
2 (0.8%)
+ Non-anatomical resection 1 (0.4%)
Non-anatomical resection/Metastectomy 181 (68.8%)
Total 705
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Figure 1 Cumulative disease-free survival of patients based on
tumour burden.
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which is a reflection of the accumulating evidence supporting the
survival benefit from resection as a result of decreased peri-
operative risk and the improvement in accuracy of imaging.
Nevertheless, despite numerous studies documenting the
importance of prognostic factors including: patient demograph-
ics; tumour characteristics; operative factors;22–24,33,34 and more
recently tumour-host biology35,36 in relation to disease recurrence
and survival after resection of CRLM, these prognostic indicators
remain inconsistent. This had lead to various authors developing
scoring systems to refine candidacy for selection and categorize
patients for clinical management. However, Zakaria et al.37
recently concluded that the application of risk scoring systems had
limited clinical value after analysis of their own scoring system
and other published scoring systems on their dataset.
The fact that prognostic factors such as tumour number and
size have been inconsistently identified suggests that these factors
do influence the outcome of patients depending on their tumour
burden at presentation but may not be the only factors worthy
of consideration. Selection criteria based on tumour number
and size is an appropriate reflection of disease burden but does
not necessarily take into account the disease biology. Hence, the
aim of this study was to determine the outcome of patients
based on the extent of disease burden that consisted of tumour
number and size, but which also took into account the effect of
tumour biology by considering the tumour’s systemic IRT and
the impact of surgical technique as represented by resection
margin status.
The data from the current study were extracted from a large,
single-institution experience. The primary finding of this study
was that patients in the high tumour burden group (higher
tumour number and larger size) had a significantly higher rate of
R1 resections and were more likely to express a systemic IRT. The
association of the expression of a systemic IRT with a greater
tumour burden is likely to be a reflection of more aggressive
disease. This may also account for the higher R1 margin present in
this group as the greater the number of metastases, the more
difficult it is to obtain a R0 resection.
With respect to outcome, the current study observed that sys-
temic IRT, blood transfusion requirements, tumour burden and
resection margin status were all independent predictors of
disease-free survival. Similarly, the presence of a systemic IRT,
extensive tumour burden and R1 resection margin were associated
with a poorer overall survival. The findings in the present study
are in agreement with the current literature, as discussed below.
Table 3 Statistical analysis of prognostic factors with respect to disease-free survival
Prognostic factors for disease-free survival Univariate
analysis
Multivariate
analysis
Hazard
Ratios
Confidence
Interval
Age 65 years (n = 343, 48.7%) 0.324 NA NA NA
Female gender (n = 259, 36.7%) 0.956 NA NA NA
Synchronous presentation (n = 298, 42.3%) 0.331 NA NA NA
IRT (n = 116, 21.4%)* <0.001 <0.001 1.551 1.217–1.975
Hemi-hepatectomy or more (n = 442, 62.7%) 0.046 0.413 0.901 0.701–1.157
Blood transfusion (n = 149, 21.1%) 0.007 0.002 1.473 1.155–1.877
High tumour burden (n = 289, 41%) <0.001 0.023 1.205 1.026–1.416
R1 margin (n = 258, 36.6%) <0.001 0.001 1.487 1.185–1.865
NA, not applicable; IRT, inflammatory response to tumour.
*IRT was available in 543 (77.0%) patients.
Table 4 Statistical analysis of prognostic factors with respect to overall survival
Prognostic factors for overall survival Univariate
analysis
Multivariate
analysis
Hazard
Ratios
Confidence
Interval
Age 65 years (n = 343, 48.7%) 0.104 NA NA NA
Female gender (n = 259, 36.7%) 0.948 NA NA NA
Synchronous presentation (n = 298, 42.3%) 0.306 NA NA NA
IRT (n = 116, 21.4%)* <0.001 <0.001 1.707 1.309–2.277
Hemi-hepatectomy or more (n = 442, 62.7%) 0.024 0.733 0.951 0.714–1.267
Blood transfusion (n = 149, 21.1%) 0.508 NA NA NA
High tumour burden (n = 289, 41%) <0.001 0.005 1.303 1.084–1.568
<0.001 0.011 1.408 1.082–1.833
R1 marginb (n = 258, 36.6%) <0.001 0.011 1.408 1.082–1.833
NA, not applicable; IRT, inflammatory response to tumour.
*IRT was available in 543 (77.0%) patients.
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Both Rosen et al.38 and Kooby and colleagues39 observed that
patients who did not receive a blood transfusion had a signifi-
cantly better outcome as assessed by univariate analysis.38
However, on multi-variate analysis incorporating other significant
clinico-pathological co-variates, blood transfusion failed to reach
significance in either study. In this series, blood transfusion
requirement was an independent predictor of tumour recurrence,
but not overall survival. One suggested underlying mechanism
of the effect of blood transfusion on survival is the alteration
in the immune function of the recipient leading to
immuno-suppression;40,41 an environment that may promote
cancer recurrence.
There is increasing evidence correlating tumour biology and
the patient’s systemic IRT with prognosis. The current series
showed that there were significantly more patients with disease
recurrence and adverse survival that exhibited an IRT. This sug-
gests that CRLM patients that express an IRT may have an
‘aggressive’ tumour biology profile, and thus, are more likely to
develop tumour recurrence. Nevertheless, the association
between inflammation, CRP and NLR with poor prognosis is
Table 5 Statistical analysis of prognostic factors influencing disease-free survival in patients with moderate tumour burden
Prognostic factors (disease-free survival) n = 262 Univariate
analysis
Multivariate
analysis
Hazard
Ratios
Confidence
Interval
Age 65 years (n = 122, 46.6%) 0.142 NA NA NA
Female gender (n = 95, 36.3%) 0.311 NA NA NA
Synchronous presentation (n = 99, 37.8%) 0.251 NA NA NA
IRT (n = 33, 16.3%)* <0.001 <0.001 2.023 1.347–3.037
Hemi-hepatectomy or more (n = 162, 61.8%) 0.437 NA NA NA
Blood transfusion (n = 61, 23.3%) 0.006 0.045 1.465 1.008–2.130
R1 margin (n = 83, 31.7%) 0.005 0.115 1.343 0.930–1.939
NA, not applicable; IRT, inflammatory response to tumour.
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Figure 2 Cumulative overall survival of patients with low tumour
burden stratified by IRT.
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complex42 and remains to be elucidated. A possible explanation is
that a systemic IRT may be indicative of a favourable environ-
ment that includes pro-angiogenic factors such as vascular
endothelial growth factor (VEGF), for the development of
metastases.43 Alternatively, systemic inflammation may reflect a
poorer host immune response to tumour, which is lymphocyte
dependent. This may lead to lymphocytopaenia and a weak infil-
tration of lymphocytes at the periphery of the tumour,35 thereby
worsening their prognosis.
The role of margin status as a predictor of recurrence after
resection for CRLM is controversial. Recently, Bodingbauer et al.
observed that resection margin and size of margin width did not
correlate significantly with survival after resection for CRLM.44 In
a series of 1019 patients, Are and co-investigators demonstrated
that a resection margin >1 cm was an independent predictor of
survival after resection for CRLM.45 However, Figueras et al.
showed that a margin width <1 cm in patients who underwent
resection for CRLM did not significantly influence recurrent
disease in a cohort of 609 patients.46 In the present series, a clear
resection margin, defined as no microscopic evidence of tumour
at or within 1 mm of the margin, was an independent predictor of
both disease-free and overall survival.
The impact of systemic IRT and resection margin on outcome
after resection of CRLM merits further discussion. On sub-group
analysis, systemic IRT was an adverse predictor for patients with
low and moderate tumour burden. Hence, in these groups, other
clinico-pathological factors exert less influence with respect to
survival. As a result of the differences in results observed with
respect to resection margin between published studies, it may be
that only a selected group of patients undergoing resection for
CRLM are influenced by a clear margin. In the present series,
sub-group analysis showed that only patients with high tumour
burden benefited from a R0 margin. This could be due to the fact
that these patients have an aggressive tumour profile and it is
crucial that complete tumour clearance is obtained. Hence, for
patients who fulfil the high tumour burden criteria, ‘down-sizing’
chemotherapy should certainly be considered prior to resection to
aid in achieving a clear resection margin. Nevertheless, with the
increased use of chemotherapy, there is an increase in prevalence
of patients undergoing hepatic resection with a background of
chemotherapy-related injury, such as steato-hepatitis47 and sinu-
soidal obstruction syndrome.48 In such cases, the quality, rather
than quantity, of the remnant liver becomes an important issue to
consider prior to extensive resection. For patients with less aggres-
sive tumour burden, other clinic-pathological factors are signifi-
cantly more likely to influence outcome. In this favourable group
of patients, adjuvant chemotherapy is likely to treat residual
disease, in particular cases of R1 resection. Further understanding
is required in the area of systemic IRT and oncological outcomes
which may lead to the development of pre-operative therapeutic
Table 6 Statistical analysis of prognostic factors influencing (a) disease-free and (b) overall survival in patients within the high tumour burden
criteria
(A)
Prognostic factors for disease-free survival Univariate
analysis
Multivariate
analysis
Hazard
Ratios
Confidence
Interval
n = 289
Age 65 years (n = 141, 48.8%) 0.983 NA NA NA
Female gender (n = 102, 35.3%) 0.795 NA NA NA
Synchronous presentation (n = 139, 48.1%) 0.562 NA NA NA
IRT (n = 67, 29.5%) 0.257 NA NA NA
Hemi-hepatectomy or more (n = 228, 78.9%) 0.381 NA NA NA
Blood transfusion (n = 56, 19.4%) 0.004 0.002 1.710 1.211–2.413
R1 margin (n = 140, 48.4%) <0.001 <0.001 1.653 1.239–2.205
(B)
Prognostic factors for overall survival Univariate
analysis
Multivariate
analysis
Hazard
Ratios
Confidence
Interval
n = 289
Age 65 years (n = 141, 48.8%) 0.018 0.002 0.558 0.387–0.804
Female gender (n = 102, 35.3%) 0.617 NA NA NA
Synchronous presentation (n = 139, 48.1%) 0.744 NA NA NA
IRT (n = 67, 29.5%)* 0.026 0.028 1.513 1.047–2.186
Hemi-hepatectomy or more (n = 228, 78.9%) 0.584 NA NA NA
Blood transfusion (n = 56, 19.4%) 0.361 NA NA NA
R1 margin (n = 140, 48.4%) <0.001 0.009 1.613 1.124–2.315
NA, not applicable; IRT, Inflammatory response to tumour.
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targets that influence the expression of tumour-related inflamma-
tory responses and this may improve survival outcomes after
resection for CRLM.
In conclusion, the extent of tumour burden based on tumour
number and size significantly influenced the outcome after
hepatic resection for CRLM. By extending the criteria for surgery,
resection margin influenced the outcome of patients in the high
tumour burden group, hence the importance of achieving good
clearance in these patients. Systemic IRT tend to influence the
outcome of patients with less aggressive disease.
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Table 7 Summary of independent clinico-pathological factors that
significantly influenced disease-free and overall survival with respect
to extent of tumour burden
Prognostic factors Tumour burden
Low Moderate High
Disease-free survival IRT IRT Blood
transfusion
Blood transfusion Resection margin
Overall survival IRT IRT Age
IRT
Resection margin
IRT, inflammatory response to tumour.
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